In this study, we took advantage of a cohort of more than 1,800 tumors recently reviewed according to the latest WHO classification criteria to study the combined impact of VHL mutations and deletions in kidney tumors of all types and to study the role of these alterations on clinical outcome. Here, VHL is linked to kidney neoplasm.